CITIUS ONCOLOGY, INC.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTOR$0.52-5.9%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Checking your notes…
| Exhibit Number · Description of Document · Registrant’s Form · Dated · Exhibit Number · Filed Herewith | ||||
|---|---|---|---|---|
| 2.1* | Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 10/24/2023 | 2.1 |
| 3.1.1 | Certificate of Incorporation of Citius Oncology, Inc. | 8-K | 08/16/2024 | 3.1 |
| 3.1.2 | Certificate of Amendment to the Certificate of Incorporation of Citius Oncology, Inc., filed with the Secretary of State of the State of Delaware on April 7, 2025. | 10-Q | 08/12/2025 | 3.2 |
| 3.2 | Bylaws of Citius Oncology, Inc. | 8-K | 08/16/2024 | 3.2 |
| 4.1 | Specimen Common Stock Certificate of Citius Oncology, Inc. | S-4 | 07/11/2024 | 4.5 |
| 4.2 | Warrant Agency Agreement, dated as of July 17, 2025, by and between Citius Oncology, Inc. and Equiniti Trust Company, LLC. | 8-K | 07/18/2025 | 4.1 |
| 4.3 | Form of Common Warrant. | 8-K | 07/18/2025 | 4.2 |
| 4.4 | Form of Placement Agent Warrant. | 8-K | 07/18/2025 | 4.3 |
| 4.5 | Form of Common Warrant. | 8-K | 09/10/2025 | 4.1 |
| 4.6 | Form of Placement Agent Warrant. | 8-K | 09/10/2025 | 4.2 |
| 4.7 | Form of Common Warrant. | 8-K | 12/10/2025 | 4.1 |
| 4.8 | Form of Pre-funded Warrant. | 8-K | 12/10/2025 | 4.2 |
| 4.9 | Form of Placement Agent Warrant. | 8-K | 12/10/2025 | 4.3 |
| 4.10 | Description of Common Stock. | 10-K | 12/27/2024 | 4.2 |
| 10.1 | Amended and Restated Registration Rights Agreement, dated as of August 12, 2024 by and between Citius Oncology, Inc. and the signatories thereto. | 8-K | 08/16/2024 | 10.1 |
| 10.2 | Amended and Restated Shared Services Agreement, dated as of August 12, 2024, by and among Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 08/16/2024 | 10.2 |
| 10.3† | 2023 Omnibus Stock Incentive Plan. | 10-K | 12/27/2024 | 10.3 |
| 10.4.1† | 2024 Omnibus Stock Incentive Plan. | 8-K | 08/5/2024 | 10.5 |
| 10.4.2† | Amendment to the Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan. | 8-K | 09/19/2025 | 10.1 |
| 10.5* | Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy’s Laboratories S.A. and Citius Pharmaceuticals, Inc. | S-4 | 11/13/2023 | 10.15 |
| 10.6.1* | Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.16 |
| 10.6.2* | Amendment No. 1 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.17 |
| 10.6.3* | Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.18 |
| 10.7 | Side Letter Agreement, dated August 12, 2024, by and by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 08/16/2024 | 10.8 |
| 10.8 | Promissory Note, dated July 18, 2023, issued by TenX Keane Acquisition to 10XYZ Holdings LP. | 8-K | 07/18/2023 | 10.1 |
| 10.9 | Promissory Note, dated October 18, 2023, issued by TenX Keane Acquisition to 10XYZ Holdings LP. | 8-K | 10/18/2023 | 10.1 | |
| 10.10.1 | Promissory Note, dated August 16, 2024, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 08/16/2024 | 10.9 | |
| 10.10.2 | Amendment to Promissory Note, dated September 10, 2025, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 09/10/2025 | 10.3 | |
| 10.10.3 | Second Amendment to Promissory Note, dated December 10, 2025, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 12/10/2025 | 10.5 | |
| 10.11 | Placement Agency Agreement, dated as of July 16, 2025, by and between Citius Oncology, Inc. and Maxim Group LLC. | 8-K | 07/18/2025 | 10.1 | |
| 10.12 | Securities Purchase Agreement, dated as of July 16, 2025, by and between Citius Oncology, Inc. and the purchasers named therein. | 8-K | 07/18/2025 | 10.2 | |
| 10.13 | Placement Agency Agreement, dated as of September 9, 2025, by and between Citius Oncology, Inc. and Maxim Group LLC. | 8-K | 09/10/2025 | 10.1 | |
| 10.14 | Form of Securities Purchase Agreement, dated as of September 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 09/10/2025 | 10.2 | |
| 10.15 | Form of Registered Direct Securities Purchase Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 12/10/2025 | 10.1 | |
| 10.16 | Form of PIPE Securities Purchase Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 12/10/2025 | 10.2 | |
| 10.17 | Form of Registration Rights Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 12/10/2025 | 10.3 | |
| 10.18 | Form of Warrant Amendment Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto. | 8-K | 12/10/2025 | 10.4 | |
| 19.1 | Insider Trading Policy. | 10-K | 12/27/2024 | 19.1 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | -- | -- | -- | X |
| 31.1 | Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 31.2 | Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 32.1 | Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. | -- | -- | -- | X |
| 97.1 | Policy Relating to Recovery of Erroneously Awarded Compensation | 10-K | 04/16/2024 | 97.1 | |
| EX-101.INS | INLINE XBRL INSTANCE DOCUMENT | -- | -- | -- | X |
| EX-101.SCH | INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | -- | -- | -- | X |
| EX-101.CAL | INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | -- | -- | -- | X |
| EX-101.DEF | INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | -- | -- | -- | X |
| EX-101.LAB | INLINE XBRL TAXONOMY EXTENSION LABELS LINKBASE | -- | -- | -- | X |
| EX-101.PRE | INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | -- | -- | -- | X |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL) | -- | -- | -- | X |
| * | Portions of this exhibit have been omitted pursuant to Item 601(b)10 of Regulation S-K or certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2) or 601(a)(5), as applicable. Citius Oncology agrees to furnish supplementally an unredacted copy such exhibit, including any omitted exhibits and schedules, to the SEC upon its request. |
|---|
| † | Indicates management contract or compensatory plan. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.